NewEdge Advisors’s Outlook Therapeutics OTLK Stock Holding History

NewEdge Advisors’s Portfolio OTLK Stock Details OTLK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,000	Closed	-$45K	–	1180
2021 Q1	$45K	Hold	1,000	–	–	﹤0.01%	1018
2020 Q4	$26K	Buy	+1,000	New	+$20.9K	﹤0.01%	967

Other funds holding OTLK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LVW Advisors Pittsford, New York $1.16B AUM 26.37% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

LNC

Lincoln National Corp Radnor, Pennsylvania $3.45B AUM 12.55% 1-Year Est. Return

NewEdge Advisors's OTLK Position: Q2 2021 in Review

NewEdge Advisors sold out of Outlook Therapeutics (OTLK) in Q2 2021, closing a stake of 1,000 shares — an estimated $45K sold.

NewEdge Advisors first reported a position in OTLK in Q4 2020 and held it in 2 quarters. The position peaked at $45K in Q1 2021. 63 funds tracked by Wall St. Rank hold OTLK as of Q2 2021.

NewEdge Advisors reported no remaining Outlook Therapeutics position as of Q2 2021 after selling out during the quarter.
NewEdge Advisors sold 1,000 Outlook Therapeutics shares in Q2 2021, an estimated $45K.
NewEdge Advisors first reported a position in Outlook Therapeutics in Q4 2020 and held it in 2 quarters.
NewEdge Advisors's Outlook Therapeutics position peaked at $45K in Q1 2021.
63 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2021.

Based on NewEdge Advisors's 13F filing for Q2 2021, filed 22 Jul 2021.